Genomic analysis reveals germline and somatic <i>PDGFRB</i> variants with clinical implications in familial infantile myofibromatosis-Reference-Cited by-同舟云学术

Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis

Published:2023-03-02 Issue:6 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Barry Kelly K.¹²^ORCID,Schienda Jaclyn²³⁴,Morrow James J.²³⁴,Al‐Ibraheemi Alyaa²⁵,Balkin Daniel M.²⁶,Church Alanna J.²⁵,Eng Whitney²³⁴,Janeway Katherine A.²³⁴^ORCID,Kamihara Junne²³⁴,Liang Marilyn G.¹²

Affiliation:

1. Dermatology Section, Division of Immunology Boston Children's Hospital Boston Massachusetts USA

2. Harvard Medical School Boston Massachusetts USA

3. Division of Hematology/Oncology Boston Children's Hospital Boston Massachusetts USA

4. Department of Pediatric Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

5. Department of Pathology Boston Children's Hospital Boston Massachusetts USA

6. Department of Plastic & Oral Surgery Boston Children's Hospital Boston Massachusetts USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30262

Reference15 articles.

1. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives

2. Fibroblastic and Myofibroblastic Tumors in Children and Adolescents

3. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer

4. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib

5. A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis